Pangen Initiates Development of Antibodies for Treatment of 'Sarinjindeugi Virus' Infectious Disease
[Asia Economy Reporter Koo Eun-mo] PanGen has begun developing antibodies for the treatment of the 'SFTS virus' infectious disease.
On the 10th, PanGen announced that it had signed a contract to jointly develop antibody drugs for the treatment of Severe Fever with Thrombocytopenia Syndrome (SFTS) by adopting patented technology owned by China's Wyclone Medical Science.
Wyclone, which signed the contract with PanGen, is a venture company based in Suzhou, China, possessing a unique antibody design method called nanobody technology. Nanobody antibodies are characterized by higher stability and antigen affinity and lower immunogenicity compared to conventional antibodies.
A PanGen official said, "Wyclone has secured specific antibody candidates capable of neutralizing all SFTS viruses found in Korea, China, and Japan, and also possesses animal models essential for efficacy testing in drug development, making it a very advantageous company for product development."
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051414165763158_1778735817.jpg)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- [Breaking] Park Sukeun, Central Labor Relations Commission Chair: "Some Gaps Narrowed Between Samsung Electronics Labor and Management"
- Is This the Peak? As Others Hesitate..."The Answer Is Clear for Surviving the KOSPI 10,000 Era"
- "If That's the Case, Why Not Just Buy Stocks?" ETFs in Name Only, Now 'Semiconductor-Heavy' and a Playground for Short-Term Traders
- "No Cure Available, Spread Accelerates... Already 105 Dead, American Infected"
PanGen holds core technologies for the development of production processes and mass production of antibody drugs and plans to accelerate the development of SFTS treatments based on its core technological competitiveness, including the launch of biosimilar products. SFTS, known as the 'SFTS virus disease,' is classified as a Class 3 legally designated infectious disease with a high fatality rate, caused by bites from wild ticks infected with the virus.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
